RE:DatametrexPerhaps those revenue improvements were already "baked in", considering that their SP has increased by around 675% YTD. Not sure about DM's core business after COVID-19 is gone.
In contrast, the current SP for SZLS is only 67% higher YTD, and SZLS will be commercializing a disruptive technology in the cancer detection space. Seems like SZLS has much better upside potential than DM, which the market has not yet fully recognized.